This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S. Over 3.3 million people are diagnosed with acne in Australia SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 20, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has granted its patent application for its Spongilla technology combination as a method for treating acne. The patent, entitled "Compositions and methods for the treatment of skin conditions" (Australian Patent No.

U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of major benchmark indices were mixed. The Santa Claus rally, which began on Dec. 24 last week, seems to have resumed gains after a day of losses on Monday.

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,022,062 shares of common stock (or pre-funded warrants in lieu thereof), series C warrants to purchase up to 2,022,062 shares of common stock and short-term series D warrants to purchase up to 2,022,062 shares of common stock at a purchase price of $2.04 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under the rules of the Nasdaq Stock Market. The series C warrants and the series D warrants have an exercise price of $2.04 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants.

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock (or pre-funded warrants in lieu thereof), series C warrants to purchase up to 2,022,062 shares of common stock and short-term series D warrants to purchase up to 2,022,062 shares of common stock at a purchase price of $2.04 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series C warrants and the series D warrants will have an exercise price of $2.04 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants.

SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter ("OTC") skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of skincare consumers who expect more from their products, their science, and the companies behind them.

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 14, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2025. "At Dermata, our mission is to bring scientifically developed innovation directly to those who need it most," said Gerry Proehl, Chairman, President, and CEO of Dermata.

- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne - - Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 - - Over 3.3 million people are diagnosed with acne in Australia - SAN DIEGO, CA / ACCESS Newswire / October 2, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted Dermata's patent application for its Spongilla technology combination as a method for treating acne. The accepted patent application, entitled "Compositions and methods for the treatment of skin conditions," (Australian Patent Application No.

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARI™ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 being held in Paris, France, from September 17-20th. Details of the abstract are as follows: Abstract Title: Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris - Results from the STAR-1 Phase 3 Study Abstract Number: P3243 The full abstract will be released on Tuesday, September 16, 2025, at 10:00pm (PST).

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18 th Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com San Diego, CA, September 16, 2025 -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata” or the “Company”), a science-driven leader in dermatologic solutions, today announced that Gerry Proehl, Founder and CEO of Dermata, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.